• Earlier in June 2026, Alvotech reported that the FDA accepted its Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio for intravenous use, while also resubmitting BLAs for AVT05 and AVT06 after enhancing its Reykjavik manufacturing facility and addressing regulatory observations.
• These regulatory milestones highlight Alvotech’s expanding biosimilar pipeline in immunology and ophthalmology and indicate progress in strengthening its quality systems under its commercialization partnerships, including with Teva.
• We’ll now examine how the FDA’s acceptance of AVT16’s application could influence Alvotech’s investment narrative and future biosimilar prospects.

We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Alvotech Investment Narrative Recap

To own Alvotech, you need to believe its growing biosimilar portfolio can convert regulatory progress into steadier product revenue, despite lumpy milestones, high debt and intense price competition. In the near term, the key catalyst is successful FDA review of AVT05 and AVT06, while regulatory scrutiny of the Reykjavik facility remains the biggest operational risk. The latest FDA acceptance for AVT16 supports the pipeline story but does not remove approval timing or inspection-related uncertainty.

The FDA’s acceptance of the AVT16 BLA, alongside prior positive data for AVT80, stands out as the most relevant recent update. Together, they underscore Alvotech’s push into immunology with Entyvio biosimilars, which could matter for future revenue if approvals follow. At the same time, the resubmission of AVT05 and AVT06 after addressing FDA observations shows how tightly short term catalysts and regulatory risk are intertwined for shareholders.

Yet while the progress on AVT16 and the AVT05 and AVT06 resubmissions helps the pipeline story, investors should also be aware that...

Alvotech's narrative projects $1.0 billion revenue and $223.4 million earnings by 2029.

Uncover how Alvotech's forecasts yield a $13.83 fair value, a 232% upside to its current price.

Exploring Other Perspectives

While consensus views the recent FDA filings as reinforcing Alvotech’s long term growth potential, the most cautious analysts highlight that their US$967.9 million 2029 revenue and US$80.0 million earnings forecasts already assume clean regulatory execution, so this new information could either ease or deepen their concerns about approval timing and partner dependence.

Explore 5 other fair value estimates on Alvotech - why the stock might be worth just $4.00!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Alvotech research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Alvotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alvotech's overall financial health at a glance.

Contemplating Other Strategies?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 44 companies with promising cash flow potential yet trading below their fair value.
• Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.